Biote Corp (BTMD) Q4 2025 Earnings Call Transcript

Why It Matters

The mixed performance underscores Biote’s shift toward higher‑margin supplement sales and aggressive commercial investment, which will determine its ability to recoup procedure revenue losses and meet ambitious growth targets.

Key Takeaways

• Q4 revenue fell 6.9% to $46.4M.
• Procedure revenue down 13% amid clinic attrition.
• Dietary supplement sales rose 16% driven by e‑commerce.
• Gross margin slipped to 68% after $1.3M recall charge.
• 2026 outlook targets >$190M revenue, $38M adjusted EBITDA.

Pulse Analysis

The hormone replacement therapy (HRT) market is entering a period of regulatory optimism, highlighted by the FDA’s recent removal of black‑box warnings for certain products. This shift, combined with Biote’s expanding e‑commerce channel, has accelerated dietary supplement sales, which now represent a growing share of total revenue. While the voluntary recall of hormone pellets added a $1.3 million inventory charge and pressured gross margins, the company’s vertical integration and 503B manufacturing capabilities provide a buffer against future supply disruptions.

Biote’s strategic emphasis on commercial expansion is evident in its sales force growth from roughly 60 to over 90 representatives, with a target of 120 in 2026. Coupled with full‑capacity practitioner training sessions, this investment aims to stabilize clinic attrition and fuel new clinic starts, a leading indicator of future procedure revenue. Although SG&A expenses fell this quarter, the planned increase in sales and technology spending will raise operating costs in the near term, tempering adjusted EBITDA but positioning the firm for scalable growth.

Looking ahead, investors must weigh margin volatility risks, especially if third‑party manufacturing becomes a larger component of the product mix. The company’s guidance of more than $190 million in revenue and over $38 million in adjusted EBITDA reflects confidence in recapturing procedure growth in the second half of 2026. Success will hinge on the effectiveness of the sales expansion, continued supplement momentum, and the ability to navigate regulatory and recall‑related challenges while maintaining profitability.